CA3124301A1 - Modified orthopoxvirus vectors - Google Patents

Modified orthopoxvirus vectors Download PDF

Info

Publication number
CA3124301A1
CA3124301A1 CA3124301A CA3124301A CA3124301A1 CA 3124301 A1 CA3124301 A1 CA 3124301A1 CA 3124301 A CA3124301 A CA 3124301A CA 3124301 A CA3124301 A CA 3124301A CA 3124301 A1 CA3124301 A1 CA 3124301A1
Authority
CA
Canada
Prior art keywords
nucleotide sequence
transgene
promoter
nucleic acid
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124301A
Other languages
English (en)
French (fr)
Inventor
John C. Bell
Michael S. HUH
Matthew Y. TANG
Adrian PELIN
Caroline J. Breitbach
Michael F. BURGESS
Steven H. BERNSTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ottawa Health Research Institute
Turnstone Biologics Corp
Original Assignee
Ottawa Health Research Institute
Turnstone Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Health Research Institute, Turnstone Biologics Corp filed Critical Ottawa Health Research Institute
Publication of CA3124301A1 publication Critical patent/CA3124301A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3124301A 2018-12-21 2019-12-20 Modified orthopoxvirus vectors Pending CA3124301A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862784372P 2018-12-21 2018-12-21
US62/784,372 2018-12-21
US201962872699P 2019-07-10 2019-07-10
US62/872,699 2019-07-10
US201962930524P 2019-11-04 2019-11-04
US62/930,524 2019-11-04
PCT/CA2019/051899 WO2020124274A1 (en) 2018-12-21 2019-12-20 Modified orthopoxvirus vectors

Publications (1)

Publication Number Publication Date
CA3124301A1 true CA3124301A1 (en) 2020-06-25

Family

ID=71100021

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3124301A Pending CA3124301A1 (en) 2018-12-21 2019-12-20 Modified orthopoxvirus vectors
CA3124287A Pending CA3124287A1 (en) 2018-12-21 2019-12-20 Modified orthopoxvirus vectors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3124287A Pending CA3124287A1 (en) 2018-12-21 2019-12-20 Modified orthopoxvirus vectors

Country Status (18)

Country Link
US (2) US20220056480A1 (enExample)
EP (2) EP3898997A4 (enExample)
JP (2) JP2022514420A (enExample)
KR (2) KR20210132003A (enExample)
CN (2) CN113661246A (enExample)
AU (2) AU2019404639A1 (enExample)
BR (2) BR112021012078A2 (enExample)
CA (2) CA3124301A1 (enExample)
CL (1) CL2021001646A1 (enExample)
CO (1) CO2021009354A2 (enExample)
EC (1) ECSP21053474A (enExample)
IL (2) IL284180A (enExample)
MX (2) MX2021007438A (enExample)
PE (1) PE20212307A1 (enExample)
PH (1) PH12021551436A1 (enExample)
SG (1) SG11202106460XA (enExample)
TW (1) TW202039851A (enExample)
WO (2) WO2020124273A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
JP7724601B2 (ja) 2017-02-03 2025-08-18 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍溶解性ウイルス療法
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
EP4061417A4 (en) * 2019-11-20 2023-10-11 University of Pittsburgh - of the Commonwealth System of Higher Education VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES
JP6915792B1 (ja) * 2020-10-01 2021-08-04 国立大学法人鳥取大学 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
JP2025503721A (ja) * 2022-01-17 2025-02-04 ノイスコム アーゲー がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター
CN119677861A (zh) * 2022-06-10 2025-03-21 特兰斯吉恩股份有限公司 表达白介素-12的重组病毒
IL318055A (en) * 2022-07-08 2025-02-01 Viromissile Inc ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF
CN119923267A (zh) * 2022-07-27 2025-05-02 阿斯利康(瑞典)有限公司 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合
CN115947797B (zh) * 2022-08-02 2024-07-05 青岛硕景生物科技有限公司 猴痘病毒重组抗原及其应用
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
CN116200349A (zh) * 2023-01-18 2023-06-02 中国医学科学院病原生物学研究所 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗
CN115927215B (zh) * 2023-01-18 2025-10-17 中国医学科学院病原生物学研究所 一种定向减毒的痘苗病毒疫苗
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
WO2026047314A1 (en) * 2024-08-28 2026-03-05 University Of Surrey Recombinant vector

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150495T5 (es) * 1993-05-19 2007-02-16 Schering Corporation Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
KR20120002613A (ko) * 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
AU2003290528A1 (en) * 2002-10-15 2004-05-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
RU2503717C2 (ru) * 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
RS65104B1 (sr) * 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
RU2696312C2 (ru) * 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
CN106520778A (zh) * 2015-09-09 2017-03-22 北京锤特生物科技有限公司 改造的白介素12及其在制备治疗肿瘤的药物中的用途
WO2018049248A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
SG11202006457YA (en) * 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors

Also Published As

Publication number Publication date
EP3898997A1 (en) 2021-10-27
WO2020124273A1 (en) 2020-06-25
WO2020124274A1 (en) 2020-06-25
IL284180A (en) 2021-08-31
CO2021009354A2 (es) 2021-11-19
KR20210132003A (ko) 2021-11-03
AU2019410148A1 (en) 2021-08-12
US20220056480A1 (en) 2022-02-24
BR112021011730A2 (pt) 2021-08-31
TW202039851A (zh) 2020-11-01
CL2021001646A1 (es) 2022-02-18
EP3898998A4 (en) 2022-10-05
US20220380799A1 (en) 2022-12-01
IL284188A (en) 2021-08-31
MX2021007439A (es) 2021-08-05
EP3898997A4 (en) 2022-11-16
BR112021012078A2 (pt) 2021-08-31
ECSP21053474A (es) 2021-11-18
AU2019404639A1 (en) 2021-08-12
EP3898998A1 (en) 2021-10-27
KR20210132002A (ko) 2021-11-03
PE20212307A1 (es) 2021-12-10
CN113661246A (zh) 2021-11-16
CA3124287A1 (en) 2020-06-25
MX2021007438A (es) 2021-09-21
JP2022514420A (ja) 2022-02-10
JP2022516006A (ja) 2022-02-24
PH12021551436A1 (en) 2021-12-06
SG11202106460XA (en) 2021-07-29
CN113454231A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
CA3124301A1 (en) Modified orthopoxvirus vectors
US20240229069A9 (en) Modified orthopoxvirus vectors
US20250381237A1 (en) Oncolytic virus expressing a car t cell target and uses thereof
US20230022757A1 (en) Modified vaccinia vectors
KR20210111237A (ko) 암세포 표적화 영역과 hvem의 세포외 도메인의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
CA3189291A1 (en) Recombinant vaccinia virus
KR102418528B1 (ko) 다중 표적화 재조합 헤르페스 심플렉스 바이러스 및 그 용도
WO2024062098A1 (en) Recombinant pseudocowpox virus encoding an interleukin-12

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240729

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203